Dr. Rahul Singhvi, President and CEO of Novavax, stated:  "We are pleased to see that both doses of VLP vaccine were well tolerated and immunogenic in older adults, which was a key question for this trial.   The finding that a higher dose of VLP vaccine could be more immunogenic in this population is particularly important since there is a significant medical need for a better vaccine for older adults.  These data show that our recombinant, VLP-vaccine technology affords great flexibility in using dose as a means to improve the possible effectiveness of the vaccine.  The data from this clinical trial and from our recent Phase II influenza vaccine study in healthy younger adults suggest that our trivalent influenza vaccine may be effective in a broad range of subjects.  Taken together, the findings from these studies are encouraging and will be useful for planning further clinical testing of our trivalent VLP influenza vaccine."

SOURCE Novavax, Inc.